Get the Stockscreener App
6.37
0.31%
0.02
After Hours:
6.37
Aligos Therapeutics Inc stock is traded at $6.37, with a volume of 150.46K.
It is up +0.31% in the last 24 hours and down -21.26% over the past month.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
See More
Previous Close:
$6.35
Open:
$6.31
24h Volume:
150.46K
Relative Volume:
0.90
Market Cap:
$39.42M
Revenue:
$2.19M
Net Income/Loss:
$-24.19M
P/E Ratio:
-0.7406
EPS:
-8.6017
Net Cash Flow:
$-82.94M
1W Performance:
+6.70%
1M Performance:
-21.26%
6M Performance:
-10.28%
1Y Performance:
+39.08%
1-Day Range:
$6.24
$6.64
1-Week Range:
$5.91
$6.76
52-Week Range:
$4.20
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
6.37 | 39.30M | 2.19M | -24.19M | -82.94M | -8.6017 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Resumed | Jefferies | Buy |
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - Investing News Network
Biotech Aligos will post first-quarter results after markets close May 7 - Stock Titan
[ARS] Aligos Therapeutics, Inc. SEC Filing - Stock Titan
Aligos Therapeutics says China pact puts HBV drug in focus amid trial updates - MSN
Aligos Therapeutics (Nasdaq: ALGS) details ESPP, auditor and pay votes - Stock Titan
Aligos’ licensing deal in China broadens trial scope, secures immediate $25m - MLex
Is Aligos (ALGS) overbought or oversold? (Drifts Higher) 2026-04-27Retail Flow - Newser
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
This micro cap biotech stock is tracking its biggest intraday gains in 11 months – here’s why a China deal has retail buzzing - MSN
(ALGS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright - The Globe and Mail
New Aligos hires get stock options for 10,700 shares under Nasdaq rule - Stock Titan
Aligos Therapeutics jumps on China licensing agreement - MSN
Aligos (ALGS) Stock: Why Margin Improvement (Institutional Demand) 2026-04-22Short Term Trading - Cổng thông tin điện tử tỉnh Tây Ninh
Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop - TipRanks
Aligos Therapeutics (NASDAQ: ALGS) signs Hep B deal with up to $420M milestones - Stock Titan
Aligos (ALGS) Stock Volume Confirmation (Wavering) 2026-04-20Earnings Season - Cổng thông tin điện tử tỉnh Lào Cai
10 Health Care Stocks Moving In Friday's Intraday Session - Sahm
H.C. Wainwright reiterates Aligos stock rating on China deal - Investing.com UK
Aligos strikes license deal with Amoytop for HBV therapy development - The Pharma Letter
This drugmaker was about to run out of cash, but a Chinese partner came to the rescue - The Business Journals
H.C. Wainwright reiterates Aligos stock rating on China deal By Investing.com - Investing.com Canada
Aligos and Xiamen Amoytop sign deal for HBV therapy - Yahoo Finance
Aligos licenses hepatitis B drug to Amoytop for $25m upfront - Investing.com India
Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates - Sahm
Jefferies reiterates Aligos Therapeutics stock rating on China deal By Investing.com - Investing.com South Africa
Jefferies reiterates Aligos Therapeutics stock rating on China deal - Investing.com
Aligos licenses hepatitis B drug to Amoytop for $25m upfront By Investing.com - Investing.com South Africa
Aligos Therapeutics Licenses Hepatitis B Drug to Xiamen Amoytop for Greater China - National Today
Aligos Therapeutics (ALGS) Secures Licensing Deal for Hepatitis B Treatment - GuruFocus
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aligos Therapeutics stock surges on China licensing deal - Investing.com
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - Investing News Network
Aligos Therapeutics stock surges on China licensing deal By Investing.com - Investing.com Canada
Aligos Therapeutics jumps 22% on Greater China deal for Hepatitis B drug (ALGS:NASDAQ) - Seeking Alpha
More than 90 million live with HBV in Greater China; Aligos signs deal - Stock Titan
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):